Since their introduction, oral contraceptives have been linked to an increased incidence of thromboembolic events. Epidemiologic studies have shown that women who use third-generation oral contraceptives containing desogestrel, gestodene, or norgestimate have a higher risk of venous thrombosis than women who use second-generation oral contraceptives containing levonorgestrel. Women who use oral contraceptives are significantly less sensitive to activated protein C. From January 1996 to December 2001, 17,577 patients were hospitalized in our department, 177 of them (1%) had confirmed diagnosis of venous thromboembolism and 15 of those (177) were women on oral contraceptive therapy. Oral contraceptives were taken from 28 days to 18 months. No other potential congenital or acquired causes of thrombosis were present before thromboembolic events occurred in these women. The discon-Deep venous thrombosis (DVT) is a serious condition producing acute risk of pulmonary embolism (thromboembolic disease, TED); DVT brings about a chronic venous disease (postthrombotic syndrome). Despite adequate treatment (heparin), approximately 5% of patients with DVT suffer from massive bleeding, and later the postthrombotic syndrome develops in approximately 50% of patients with proximal DVT and 30% of those with distal DVT. Pulmonary embolism (PE) occurs in about 5% of patients with DVT. Clinical diagnosis is established in approximately 30% of all cases of PE. However, it has to be pointed out that known and adequately treat-
tinuation of the pill combined with usual heparin (in one patient thrombolysis) and coumarin therapy was effective in all cases. After the discontinuation of coumarin (3-6 months), every patient was screened for hereditary thrombophilia. All women on oral contraceptive therapy had confirmed hereditary risk factors for venous thrombosis. Acquired resistance to activated protein C may explain the epidemiologic observation of increased risk of venous thrombosis in oral contraceptive users, especially in women using third-generation oral contraceptives who had other risk factors (hereditary or acquired) for venous thrombosis. Key Words: Oral contraceptives-Deep venous thrombosis-Thromboembolic events-Pulmonary embolism-Acquired resistance to activated protein C. ed pulmonary embolism has a mortality of 10%, while in unknown and non-treated cases, it is 30% (1) (2) (3) (4) . The first literature reference regarding the relationship between oral contraceptives (OCP) and TED dates to 1961, when Dr. Jordan, a general practitioner, described the case of a 40year-old woman who suffered from PE 10 days after discontinuation of mestranol and norethynodrel, dosed for endometriosis (5) . The article had not been accepted in medical community at that time. But an increased occurrence of thromboembolic events related to OCP use was described in next article in 1967 (6) . During next 30 years, numerous studies took place with an attempt to discover mechanism through which the OCP brings about TED. There was a deep disappointment for a long period. Despite numerous studies, the mechanism of increased incidence of TED related to OCP treatment could not be sufficiently explained. Epidemiologic studies designed to detect the interaction between newly discovered congenital defects of coagulation causing thrombophilic the OCP use present a great advance. The Leiden Thrombophilia Study is one of those studies (7) . Women with the factor V Leiden (FVL), a gene mutation of factor V (FV), become less sensitive to proteolytic inactivation through activated protein C. Their risk of TED is eight times higher. Those taking the OCPs have a risk only four times higher. If FVL and administration of the OCP are simultaneously present, the risk increases thirty times. It follows that both factors have synergistic effect to hypercoagulable state (7) . Initially, a high dose of estrogen was considered the reason for OCP thrombogenity. The first-generation OCPs contained 100 mg and more of estrogens. The second-generation OCPs contains less than 50 mg of estrogen, while the third-generation OCPs contain 20 mg or less of estrogen. The OCPs also contain gestagens. Gestagens also underwent development to minimize side effects. The thirdgeneration gestagens contained in the third-generation OCPs have a minimum androgen effect. There are minimal adverse effects (8, 9) . The results from recent epidemiologic studies have been a great surprise. Women taking the third generation OCPs have a TED risk that is two times higher compared to those taking the second generation OCPs. The risk of TED multiplies for women taking OCP and simultaneously suffering from unknown congenital hypercoagulable state, most frequently FVL, or the other TED risk factor (10, 11) .
MATERIALS AND METHODS

Subjects
There were 17,577 patients treated in The Internal Department 1 in Martin from January 1, 1996 until December 31, 2001. One hundred seventy-seven patients were diagnosed with TED, DVT with or without pulmonary embolism. There were 15 women who took the third generation OCPs in that group; 11 patients took Cilest tablets and four took Femoden tablets for a period of 28 days to 18 months until TED developed. Fourteen women from 20 to 51 years old represented the group. The women took the OCPs for its contraceptive effect, and a 54-year-old female used the OCPs as hormone replacement therapy to prevent osteoporosis. There were three women with ileofemoral DVT confirmed by Doppler ultrasound admitted. There were four women with pulmonary embolism without confirmed DVT admitted. The pulmonary embolism was confirmed four times by perfusion lung scan and once by pulmonary arteriography. Seven women suffered simultaneously from DVT proven by a Doppler ultrasound and from PE proven by perfusion lung scan. All women had positive D-dimer at admission. There were seven cases of electrocardiographic signs of right overload. Anteroposterior projection chest radiographs were negative in 12 cases, changes were present in two cases. There were two cases of left-sided pleuropneumonia, another one on the right side and one case of bilateral fluidothorax. Pulmonary hypertension was detected seven times via transthoracal echocardiography. Fig. 1A shows the electrocardiography (ECG) pattern of a 51-year-old woman with a 5-day history of dyspnea. Figure lb shows the ECG pattern from the same patient 2 months before admission, asymptomatic at that time. The added perfusion lungs scan on the first day proved PE, as it can be seen on Fig. 2 . There are bilateral perfusion defects predominantly on the left side of the lung. Fig. 3A and 3B illustrate the transthoracal echocardiography of the heart showing signs of overload of the right ventricle resulting from pulmonary hypertension; a 51year-old woman without signs of DVT was admitted with acute dyspnea. Fig. 4 shows pulmonary arteriography of a 26-year-old woman that confirms expected pulmonary embolism. In this case a thrombolytic therapy for continuous severe hypotension was indicated. Full-dose heparin anticoagulation was used 13 times and a thrombolysis treatment by tissue plasminogen twice. The treatment was successful in 100% of cases. The patients were discharged on oral anticoagulation treatment to outpatient care. The OCP was discontinued. The anticoagulation treatment of the patients with DVT and without PE took 3 months, while those suffering from PE were treated for 6 months. The patients have been followed up in the Hematological Department of our hospital.
Methods
The following examinations had been completed: antithrombin III, APC ratio (response to activated C protein through activated partial thromboplastin time [aPTT]), in the case of APC resistance the genetic examination to FVL, furthermore the C and S protein (their activity), in the case of low activity and their amount (antigen), aPTT-LA (lupus anticoagulant), antiphospholipid antibodies (APA), HCII (heparin cofactor II), factor XII, fibrinogen, homocysteine, and also genetic examination for prothrombin 20210A since 1998. In instances with acute thrombosis the examination did not take place, for example, those involving C and S protein.
These were completed after the anticoagulation therapy was over. All female patients underwent examination both on the first day and after a period of time (3 months for the patients with DVT and without PE, and 6 months for the patients with PE, with or without DVT) after discontinuation of anticoagulation therapy due to the hy-percoagulable state. The enzyme-linked immunosorbent assay and coagulation methods were used for rating of the individual examinations. The activity was first determined for antithrombin III, HC II, C and S protein as well as factor VII and factor XII. Antigen was also determined with its lower amounts. The amount of antigen with degraded function had always been reduced for the patients in our group.
RESULTS
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APC resistance was detected in a total of eight female patients and in six of these cases, FVL was identified. The patients were recognized as heterozygous and four of them were thrombophilic during previous gravidity. Prothrombin 20210A was detected in two of them, they were also recognized as heterozygous and had a positive family history for TED, two patients suffered from C protein deficit, two suffered from both C and S~~~~~p rotein deficit, one patient was positive for APA ;X;;;X;CSand without signs of systemic impairment. She suffered from venous thrombosis during previous gravidity. See Table 1 for review of the examination results.
DISCUSSION
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is caused by plasma proteasis coagulation in- sensitive to proteolytic inactivation through activated C protein [APC] (12) ) demonstrates physiologic significance of coagulation inhibitors. Enhanced risk of venous thromboembolism is associated with OCP administration in healthy women. Although both the retrospective and prospective studies proved four to nine times higher risk of venous thrombosis for women taking OCP, there are small changes in hemostatic data in the group with the OCP treatment, and they remain within the limits. The response to APC and measured aPTT remains within the standard (13) . In the past, the higher risk of venous thrombosis associated with OCP use was believed to be due to estrogen's effect on the coagulation system. This resulted in development of new OCP types with gradually lower estrogen content. However, the number of thromboembolic cases had not dropped, it rather increased. Attention has been focused on the gestagen component of the OCP. The antibodies against cyproter acetate (progestin composition belonging to the third gestagen generation) were suspected, and that was later proven. These antibodies are able to cause thrombosis of iliac veins through imunocomplex pathway, which typically occurs at the OCP users. Isolated thrombosis of iliac veins may be asymptomatic and temporary if it does not spread to ileofemoral area. It may also produce pulmonary embolism (14) . The mentioned authors detected the APC influence to thrombin formation in plasma and gathered information on sensitivity to APC. The results of the women who did not take the OCP and those who took the OCP confirm that the OCPs cause acquired APC resistance. The significant differences in sensitivity to APC were found between OCP users and nonusers. The group representing the OCP users, the users of the monophasic third-generation OCPs, had significantly lesser sensitivity to APC than those taking the second-generation OCPs as well as the triphasic third-generation OCPs. The users of the monophasic third-generation OCP had similar reaction to APC as the FVL heterozygotes. Acquired APC resistance may explain higher risk of venous thrombosis among the users of OCPs. The users of the third-generation OCPs have the reaction to APC similar to FVL heterozygotes taking no OCP. The reaction to APC in heterozygous women taking the OCP, in whom the FVL is impaired, is the same as the reaction of the FVL homozygotes taking no OCPs. These facts prove that the women taking the third-generation OCPs suffer from venous thrombosis seven to eight times more often than those without FVL and taking no OCPs. This is similar to the women taking no OCP and who are FVL heterozygous. However, the FVL heterozygous women who take the third-generation OCPs are at risk of venous thrombosis that is 30-50 times higher than those taking no OCP, which approximately matches the FVL homozygous women taking no OCP. The same physiologic process (12) most probably causes more cases of venous thrombosis with congenital APC resistance (FVL) than the acquired APC. These are valuable data on the mechanism of OCP's effect. The graph also proves that the women taking the OCP are at risk of venous thrombosis during the first 21 days while taking the medication. The examination of the response to APC sensibility through aPTT in women taking no OCP shows minimal differences. The examination of the response to APC through endogenous thrombin formation (ETP) is a method that launches the coagulation in extrinsic way in comparison to aPTT where the coagulation is launched intrinsically. These facts support the influence of antibodies to cyproteron acetate with minimal participation in the increase of acquired APC resistance (12, 14) . CONCLUSION Today's OCPs form a heterogeneous group of medications that have contraceptive and other positive and negative effects. The OCP have their indications as well as currently known contraindications (9, 15) . Gynecologists prescribe OCPs, but cardiologists diagnose and treat complications. Recent epidemiologic studies (10,11) confirmed a higher occurrence of TED in women taking third-generation OCPs, particularly in the patients having congenital hypercoagulable state. The examinations designed to reveal congenital hypercoagulable state are time-consuming. They are not indicated for all women before intended OCP administration. The third-generation OCP should not be administered to women with an assumed congenital hypercoagulable state due to the OCP contraindications described in literature and the results from recent epidemiologic studies (10, 11) . It concerns women with a history of venous thrombosis or hypertension during a previous pregnancy as well as a history of venous thrombosis of pregnancy and also women with a positive family history of TED, overweight women, and women who smoke (7, 10, 11) . The patients with high risk (with personal or family history of TED) should be screened for a congenital hypercoagulable state. If a genetic defect is found, the second-generation OCP should be used in heterozygous women with strict supervision, concentrating on possible venous thrombosis especially when other risk factors of venous thrombosis are present (16) . Preferably another type of contraception should be used in homozygous women (16) . It is also recommended that all OCP users have prevention of DVT (16) if other risk factors of venous thrombosis (planned surgery, immobilization) are present. From a practical point of view, the personal history requires the question referring to OCP administration either at present or during the previous 3 months (7) in differential diagnosis and treatment of young women with DVT or attacks of dyspnea.
